Research location
Westlake Village
California, United States
Advertisement
Research activity in Westlake Village
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 79 trials and 80 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Westlake Village
79 linked trials · page 1 of 2This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853 · 2025-09-28 · 1 site observation
RECRUITING
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant HypertensionNCT06343298 · 2024-11-17 · 1 site observation
RECRUITING
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)NCT07400653 · 2026-02-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseNCT06760637 · 2025-01-06 · 1 site observation
ACTIVE_NOT_RECRUITING
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · 2023-04-03 · 1 site observation
COMPLETED
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsNCT05571839 · 2023-01-03 · 1 site observation
TERMINATED
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · 2022-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · 2022-07-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299 · 2022-07-20 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast CancerNCT05132582 · 2022-03-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerNCT04539938 · 2020-12-01 · 1 site observation
COMPLETED
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerNCT03701334 · 2018-12-07 · 1 site observation
ACTIVE_NOT_RECRUITING
PROMINENT-Eye Ancillary Study (Protocol AD)NCT03345901 · 2018-01-15 · 1 site observation
TERMINATED
Anti-VEGF Treatment for Prevention of PDR/DMENCT02634333 · 2016-01-01 · 1 site observation
COMPLETED
A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.NCT02639832 · 2015-12-01 · 1 site observation
UNKNOWN
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)NCT01942135 · 2013-09-26 · 1 site observation
COMPLETED
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to OlmesartanNCT01876368 · 2013-09-01 · 1 site observation
COMPLETED
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic SettingNCT01808573 · 2013-03-29 · 1 site observation
COMPLETED
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)NCT01740427 · 2013-02-22 · 1 site observation
COMPLETED
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular DiseaseNCT01609582 · 2012-06-01 · 1 site observation
TERMINATED
8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With HypertensionNCT01570686 · 2012-04-01 · 1 site observation
COMPLETED
Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 HypertensionNCT01508026 · 2012-01-01 · 1 site observation
COMPLETED
Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRONCT01465802 · 2011-12-26 · 1 site observation
COMPLETED
Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes MellitusNCT01414920 · 2011-08-01 · 1 site observation
COMPLETED
Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 HypertensionNCT01415505 · 2011-08-01 · 1 site observation
COMPLETED
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung CancerNCT01360554 · 2011-06-16 · 1 site observation
COMPLETED
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-InhibitorNCT01283971 · 2011-05-01 · 1 site observation
TERMINATED
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes MellitusNCT01306214 · 2011-02-01 · 1 site observation
COMPLETED
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 DiabetesNCT01243424 · 2010-11-11 · 1 site observation
COMPLETED
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung CancerNCT01237678 · 2010-11-01 · 1 site observation
TERMINATED
A Study in Participants With Rheumatoid Arthritis on Background Methotrexate TherapyNCT01185353 · 2010-10-01 · 1 site observation
COMPLETED
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 WeeksNCT01183013 · 2010-08-01 · 1 site observation
COMPLETED
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)NCT01147250 · 2010-06-01 · 1 site observation
COMPLETED
Study of KB003 In Biologics-Inadequate Rheumatoid ArthritisNCT00995449 · 2010-01-01 · 1 site observation
TERMINATED
Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid ArthritisNCT01008852 · 2009-12-01 · 1 site observation
COMPLETED
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus GlimepirideNCT00968812 · 2009-09-01 · 1 site observation
COMPLETED
Olmesartan Comparison to Losartan in Hypertensive SubjectsNCT00949884 · 2009-08-01 · 1 site observation
COMPLETED
A Study in Patients With Rheumatoid ArthritisNCT00966875 · 2009-08-01 · 1 site observation
COMPLETED
A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast CancerNCT00938652 · 2009-07-01 · 1 site observation
COMPLETED
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerNCT00887536 · 2009-05-01 · 2 site observations
COMPLETED
INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic DrugsNCT00902486 · 2009-05-01 · 1 site observation
COMPLETED
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)NCT00891020 · 2009-05-01 · 1 site observation
COMPLETED
Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With GastroparesisNCT00845858 · 2009-04-01 · 1 site observation
COMPLETED
A Study for Participants With Type 2 Diabetes MellitusNCT00871572 · 2009-03-01 · 1 site observation
COMPLETED
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe HypertensionNCT00860262 · 2009-03-01 · 1 site observation
COMPLETED
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailureNCT00853658 · 2009-03-01 · 1 site observation
COMPLETED
Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic PainNCT00838799 · 2009-02-01 · 1 site observation
COMPLETED
A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.NCT00755287 · 2008-11-01 · 1 site observation
COMPLETED
A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood PressureNCT00791258 · 2008-11-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.